Assumptions based on the inclusion and exclusion criteria and observed 2-year MACE, TLR, and MI rates in SPIRIT II & III 2 year analysis.
* XIENCE V has demonstrated statistical superiority in the primary endpoints of SPIRIT IV, SPIRIT III and SPIRIT II in target lesion failure, in-segment late loss and in-stent late loss respectively. Source: SPIRIT IV 1-year results, Gregg Stone, TCT 2009 and XIENCE V IFU. TAXUS Express was the control in SPIRIT IV.
Both TAXUS Express (73% lesions) and TAXUS Liberte (27% lesions) were used as controls in SPIRIT II. TAXUS Express was used as the control in SPIRIT III.
1
| † |
MACE = cardiac death, MI, ID-TLR by CABG or PCI. |